Have Insiders Sold Neuronetics Shares Recently?

Investors may wish to note that the Senior VP of Neuronetics, Inc., Stephen Furlong, recently netted US$98k from selling stock, receiving an average price of US$6.13. On the bright side, that’s just a small sale and only reduced their holding by 10.0%.

View our latest analysis for Neuronetics

The Last 12 Months Of Insider Transactions At Neuronetics

In the last twelve months, the biggest single sale by an insider was when the President, Keith Sullivan, sold US$236k worth of shares at a price of US$3.72 per share. So it’s clear an insider wanted to take some cash off the table, even below the current price of US$6.03. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can’t be sure if it does mean insiders think the shares are fully valued, so it’s only a weak sign. This single sale was just 17% of Keith Sullivan’s stake.

Insiders in Neuronetics didn’t buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGM:STIM Insider Trading Volume January 21st 2023

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.


Insider Ownership Of Neuronetics

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 3.5% of Neuronetics shares, worth about US$5.8m, according to our data. Overall, this level of ownership isn’t that impressive, but it’s certainly better than nothing!

What Might The Insider Transactions At Neuronetics Tell Us?

An insider sold stock recently, but they haven’t been buying. Looking to the last twelve months, our data doesn’t show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we’re not particularly excited about the stock. So we’d only buy after very careful consideration. So while it’s helpful to know what insiders are doing in terms of buying or selling, it’s also helpful to know the risks that a particular company is facing. To assist with this, we’ve discovered 3 warning signs that you should run your eye over to get a better picture of Neuronetics.

If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

What are the risks and opportunities for Neuronetics?

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.

View Full Analysis

Rewards

  • Revenue is forecast to grow 16.87% per year

Risks

  • Shareholders have been diluted in the past year

  • Significant insider selling over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.